(UroToday.com) Current guidelines for initial staging of intermediate- and high-risk prostate cancer recommend the use of cross-sectional imaging and bone scan, whereas the local staging of prostate cancer relies on systematic or targeted biopsies and multiparametric magnetic resonance imaging (mpMRI). However, the role of prostate-specific membrane antigen (PSMA)-targeted PET in the evaluation of intraprostatic cancer foci and T-staging assessment is not well defined. At the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU), Dr. Ida Sonni and colleagues from UCLA presented results of their study comparing the diagnostic performance of PSMA PET/CT, mpMRI and the combination of the two modalities (PSMA PET/CT plus mpMRI) in the detection, intra-prostatic localization, and local extension of primary prostate cancer with histopathology as the gold standard.